Cystic fibrosis carriers have higher neonatal immunoreactive trypsinogen values than non-carriers

American Journal of Medical Genetics

Volumn 135 A, Issue 2, 2005, Pages 142-144

  Castellani, Carlo ^a   Picci, Luigi ^b   Scarpa, Maurizio ^b   Dechecchi, Maria Cristina ^a   Zanolla, Luisa ^c   Assael, Baroukh Maurice ^a   Zacchello, Franco ^b  

^a UNIVERSITY HOSPITAL OF VERONA   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

Author keywords

CF heterozygotes; Immunoreactive trypsinogen; Neonatal screening

Indexed keywords

TRYPSINOGEN;

ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; GENETIC ANALYSIS; HETEROZYGOSITY; HUMAN; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; NEWBORN; NEWBORN SCREENING; PRIORITY JOURNAL;

CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DNA MUTATIONAL ANALYSIS; GENETIC SCREENING; HETEROZYGOTE; HUMANS; IMMUNOASSAY; INFANT, NEWBORN; ITALY; MUTATION; NEONATAL SCREENING; PANCREATIC FUNCTION TESTS; TRYPSINOGEN;

EID: 20044388767     PISSN: 15524825     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajmg.a.30470     Document Type: Article

References (11)

1. Boyne J, Evans S, Pollitt RJ, Taylor CJ, Dalton A. 2000. Many ΔF508 heterozygote neonates with transient hypertrypsinemia have a second, mild CFTR mutation. J Med Genet 37:543-547.
2. Castellani C, Bonizzato A, Mastella G. 1997. CFTR mutations and FVS8-5T variant in newborns with hypertrypsinemia and normal sweat test. J Med Genet 34:297-301.
3. Castellani C, Benetazzo MG, Tamanini A, Begnini A, Mastella G, Pignatti PF. 2001a. Analysis of the entire coding region of the cystic fibrosis transmembrane regulator gene in neonatal hypertrypsinemia with normal sweat test. J Med Genet 38:202-205.
4. Castellani C, Quinzii C, Altieri S, Mastella G, Assael BM. 2001b. A pilot survey of cystic fibrosis clinical manifestations in CFTR mutation heterozygotes. Genetic Testing 5:249-254.
5. Dankert-Roelse JE. 1994. Neonatal screening. In: Dodge JA, Brock DJH, Widdicombe JH, editors. Cystic fibrosis-Current topics. Wiley and sons. Chichester, New York, Brisbane, Toronto, Singapore, pp 303-318.
6. Hanley JA, McNeil BJ. 1982. The meaning and use of the area under a Receiver Operating Characteristic (ROC) Curve. Radiology: 143:29-36.
7. Laroche D, Travert G. 1991. Abnormal frequency of 7F508 mutation in neonatal transitory hypertrypsinaemia. Lancet 337:55.
8. Lecoq I, Brouard J, Laroche D, Ferec C, Travert G. 1999. Blood immunoreactive trypsinogen concentrations are genetically determined in healthy and cystic fibrosis newborns. Acta Paediatr 88:338-341
9. Massie RJ, Wilcken B, Van Asperen P, Dorney S, Gruca M, Wiley V, Gaskin K. 2000. Pancreatic function and extended mutation analysis in DeltaF508 heterozygous infants with an elevated immunoreactive trypsinogen but normal sweat electrolyte levels. J Pediatr 137:214-220.
10. Scotet V, De Braekeleer M, Audrezet M-P, Lode L, Verlingue C, Quere I, Mercier B, Dugueperoux I, Codet JP, Moineau MP, Parent P, Ferec C. 2001. Prevalence of CFTR mutations in hypertrypsinaemia detected through neonatal screening for cystic fibrosis. Clin Genet 59:42-47.
11. Welsh MJ, Smith AE. 1993. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 73:1251-1254.